Allogene Therapeutics, Inc. (ALLO)
1.69
-0.04
(-2.31%)
USD |
NASDAQ |
Sep 18, 16:00
1.685
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Enterprise Value : 330.04M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 330.04M |
| September 17, 2026 | 343.85M |
| September 16, 2026 | 330.04M |
| September 15, 2026 | 340.40M |
| September 14, 2026 | 361.12M |
| September 11, 2026 | 361.12M |
| September 10, 2026 | 354.21M |
| September 09, 2026 | 343.85M |
| September 08, 2026 | 388.75M |
| September 04, 2026 | 426.74M |
| September 03, 2026 | 430.19M |
| September 02, 2026 | 430.19M |
| September 01, 2026 | 431.92M |
| August 31, 2026 | 437.10M |
| August 28, 2026 | 444.00M |
| August 27, 2026 | 468.18M |
| August 26, 2026 | 450.91M |
| August 25, 2026 | 495.80M |
| August 24, 2026 | 447.46M |
| August 21, 2026 | 468.18M |
| August 20, 2026 | 471.63M |
| August 19, 2026 | 516.53M |
| August 18, 2026 | 447.46M |
| August 17, 2026 | 464.72M |
| August 14, 2026 | 454.36M |
| Date | Value |
|---|---|
| August 13, 2026 | 430.19M |
| August 12, 2026 | 461.27M |
| August 11, 2026 | 478.54M |
| August 10, 2026 | 471.63M |
| August 07, 2026 | 440.55M |
| August 06, 2026 | 426.74M |
| August 05, 2026 | 419.83M |
| August 04, 2026 | 402.56M |
| August 03, 2026 | 381.84M |
| July 31, 2026 | 395.65M |
| July 30, 2026 | 426.74M |
| July 29, 2026 | 371.48M |
| July 28, 2026 | 319.68M |
| July 27, 2026 | 350.76M |
| July 24, 2026 | 347.31M |
| July 23, 2026 | 374.93M |
| July 22, 2026 | 388.75M |
| July 21, 2026 | 385.29M |
| July 20, 2026 | 357.67M |
| July 17, 2026 | 364.57M |
| July 16, 2026 | 364.57M |
| July 15, 2026 | 402.56M |
| July 14, 2026 | 385.29M |
| July 13, 2026 | 412.92M |
| July 10, 2026 | 437.10M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cartesian Therapeutics, Inc. | 157.45M |
| Beam Therapeutics, Inc. | 1.671B |
| Kyverna Therapeutics, Inc. | 272.57M |
| Arrowhead Pharmaceuticals, Inc. | 9.157B |
| Oncolytics Biotech, Inc. | 92.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -42.68M |
| Revenue (Quarterly) | 4.64M |
| Total Expenses (Quarterly) | 47.32M |
| EPS Diluted (Quarterly) | -0.1297 |
| Gross Profit Margin (Quarterly) | 43.00% |
| Profit Margin (Quarterly) | -919.8% |
| Earnings Yield | -39.36% |
| Normalized Earnings Yield | -39.36 |